Assess the Efficacy and Safety of RESTORE Paclitaxel Eluting Balloon Versus RESOLUTE Zotarolimus Eluting Stent for the Treatment of Small Coronary Vessel Disease
NCT ID: NCT02946307
Last Updated: 2019-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
240 participants
INTERVENTIONAL
2016-08-31
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis
NCT02944890
Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions
NCT05209412
ACOART Paclitaxel SVD:Paclitaxel Coated Coronary Balloon Catheter in Treatment of Coronary Small Vessel Diseases
NCT04626687
Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent Restenosis
NCT04213378
Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis
NCT01967199
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
small vessel cohort:Restore DEB
receiving the treatment with Restore DEB（dimeter\>2.00 mm） in small vessel cohort
Restore DEB（dimeter>2.00 mm）
small vessel cohort:Resolute DES
receiving the treatment with Resolute DES in small vessel cohort
Resolute DES
very small vessel cohort:Restore DEB
receiving the treatment with Restore DEB（dimeter:2.00 mm）in very small vessel cohort
Restore DEB（dimeter:2.00 mm）
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Restore DEB（dimeter>2.00 mm）
Resolute DES
Restore DEB（dimeter:2.00 mm）
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age ≥18 years old
2. Patients with stable or unstable angina pectoris, or recent myocardial infarction which has been stabilized (occurred over 7 days before enrollment, including non-st segment elevation myocardial infarction(NSTMI) and STMI), or proved asymptomatic regional myocardial ischemia
3. Patients in the small vessel cohort should be suitable for balloon dilation angioplasty or stent implantation, patients in the very small vessel cohort should be suitable for balloon dilation angioplasty.
4. Patients should have sufficient compliance and agree to receive follow-ups in month-1, 6, 9 and 12, and follow-up visit in year-2, 3, 4, and 5. It is required to perform angiography in month-9.
5. Patients should volunteer to participate in this study, and sign the written informed consent form, and understand all risks and benefits in the informed consent document.
Related to the diseases:
6. Patients with de novo, in situ lesions of small coronary vessels, the length of the lesion should be ≤26mm according to visual inspection. In the small vessel cohort, the diameter of the target lesion should be ≥2.25mm and ≤2.75mm according to visual inspection, and in the very small vessel cohort, the diameter of the target lesion should be ≥2. 00mm and \<2.25mm according to visual inspection.
7. The diameter stenosis according to visual inspection before intervention treatment should be ≥70% or ≥50% with the evidence of ischemia.
8. Each patient is allowed to have only one lesion of the target small vessel (2 lesions with the distance ≤10mm and total length ≤26mm which could be treated with the same balloon or stent is considered as one lesion).
Exclusion Criteria
1. Myocardial infarction occurred within 1 week before enrollment.
2. Patients with severe congestive heart failure or New York Heart Association (NYHA) grade IV heart failure
3. Left ventricular ejection fraction (LVEF) \<35%
4. Patients who had heart transplantation
5. Patients with severe valvular heart disease
6. The patients had cerebral stroke within 6 months before being included, or have a history of peptic ulcer or gastrointestinal bleeding in the past 6 months, or the patients have a bleeding tendency according to the investigator.
7. Patients with a history of leukopenia (white blood cell count \<3×109/L for more than 3 days) or neutropenia (ANC\<1000/mm3 for more than 3 days) or thrombocytopenia (platelet \<100,000/mm3)
8. Patients with renal insufficiency (eGFR\<30ml/min)
9. Patients who are forbidden to use anticoagulation agents or anti-platelet drugs, and unable to tolerate Aspirin or Clopidogrel
10. Patients who are known to be allergic to Paclitaxel or Zotarolimus
11. The patients have a life expectancy of less than 1 year, or it would be difficult to finish follow-ups within 1 year.
12. Pregnant or lactating women, or female patients at a child-bearing age who plan to get pregnant during the period of the study or could not take effective contraceptives
13. The patients are participating in any clinical trials of other drugs or devices before reaching the primary endpoints.
14. Patients who are unsuitable for the study according to the investigator due to other reasons
Related to the diseases:
15. Patients with total occlusion of the target vessel
16. The patients have severe calcification of the target lesion, and therefore balloon pre-dilation could not be performed successfully.
17. The target lesions are bifurcation lesion with the diameter of the branch vessel \>2.00mm.
18. The target lesions are in-stent restenosis.
19. Angiography indicates thrombosis in the target vessel.
20. Complicated with lesions in left main(LM) requiring intervention treatment
21. There are more than 2 non-target lesions which require treatment, or could not be treated with intervention before the target lesion, or the treatment had failed.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
R&G Pharma Studies Co.,Ltd.
INDUSTRY
ZhuHai Cardionovum Medical Device Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Runlin Gao, Master
Role: PRINCIPAL_INVESTIGATOR
Chinese Academy of Medical Sciences, Fuwai Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Anzhen Hospital,Capital Medical University
Beijing, Beijing Municipality, China
Fuwai Hospital, CAMS&PUMC
Beijing, Beijing Municipality, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Daqing Oilfield General Hospital
Daqing, Heilongjiang, China
Wuhan Asia Heart Hospital
Wuhan, Hubei, China
Xiangya Hospital Central South University
Changsha, Hunan, China
Nanjing Drum Tower Hospital, The Affiliated Hospital of Najing University Medical School
Nanjing, Jiangsu, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
Tangdu Hospital
Xi'an, Shaanxi, China
Tianjin 4th Centre Hospital
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Li L, Guan C, Meng S, Bai Y, Zhang Z, Zou K, Ruan Y, Cao X, Jia R, Guo C, Escaned J, Jin Z, Xu B. Short- and long-term functional results following drug-coated balloons versus drug- eluting stents in small coronary vessels: The RESTORE quantitative flow ratio study. Int J Cardiol. 2021 Mar 15;327:45-51. doi: 10.1016/j.ijcard.2020.11.035. Epub 2020 Nov 21.
Tang Y, Qiao S, Su X, Chen Y, Jin Z, Chen H, Xu B, Kong X, Pang W, Liu Y, Yu Z, Li X, Li H, Zhao Y, Wang Y, Li W, Tian J, Guan C, Xu B, Gao R; RESTORE SVD China Investigators. Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial. JACC Cardiovasc Interv. 2018 Dec 10;11(23):2381-2392. doi: 10.1016/j.jcin.2018.09.009.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RG01W-1102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.